title: Orexin 2 receptor as a potential target for immunotoxin and antibody-drug conjugate cancer therapy.
abstract: Targeting tumor-specific receptors is a promising approach for cytotoxic agents. The orexin 2 receptor (OX2R) has reportedly been expressed in a few types of cancer, but not in normal, cells. This study aimed to explore and assess the expression levels of OX2R in a wide range of cancer cell lines and clinical samples to identify its localization. To analyze OX2R expression, we developed a polyclonal antibody specific to OX2R by immunizing two rabbits with a peptide cocktail. A total of 36 cancer cell lines were employed for reverse transcription polymerase chain reaction (RT-PCR) and western blot analysis, and 221 samples from various tissue arrays were used for the immunohistochemistry of OX2R expression. OX2R was identified in three cancerous cell lines, from the gallbladder, squamous cell carcinoma of the head and neck (SCCHN) and glioblastoma. With clinical samples of tissue arrays, 69/221 (31.2%) samples reacted positively with the OX2R antibody. We confirmed its presence on the cell membrane. In conclusion, OX2R was identified on several cancer cells as well as clinical samples. Further studies with larger numbers of clinical samples are required to confirm the statistical significance of the presence and relationships of OX2R with tumor histology. Results of the current study suggested that OX2R is a potent target for immunotoxin or antibody-drug conjugate (ADC) cancer therapy on OX2R-positive cancer cells.
authors: Department of Biomedical Chemistry, Graduate school of Medicine, The University of Tokyo, Tokyo 113-0033.
authors: Masato
authors: M
authors: Kishida
authors: Kazunori
authors: K
authors: Ishige
authors: Tomohisa
authors: T
authors: Horibe
authors: Noriko
authors: N
authors: Tada
authors: Nobutaka
authors: N
authors: Koibuchi
authors: Junichi
authors: J
authors: Shoda
authors: Kiyoshi
authors: K
authors: Kita
authors: Koji
authors: K
authors: Kawakami